Sphera Funds Management LTD. boosted its stake in CytomX Therapeutics Inc (NASDAQ:CTMX) by 180.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 233,151 shares of the biotechnology company’s stock after buying an additional 150,009 shares during the period. Sphera Funds Management LTD.’s holdings in CytomX Therapeutics were worth $4,313,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Great West Life Assurance Co. Can raised its holdings in CytomX Therapeutics by 174.6% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 3,143 shares during the period. SG Americas Securities LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $119,000. Capital Fund Management S.A. purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $247,000. Tiff Advisory Services Inc. purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $320,000. Finally, Fox Run Management L.L.C. purchased a new stake in CytomX Therapeutics in the 3rd quarter valued at about $225,000. Hedge funds and other institutional investors own 83.79% of the company’s stock.
Shares of NASDAQ:CTMX opened at $14.09 on Friday. The stock has a market cap of $622.45 million, a price-to-earnings ratio of -12.15 and a beta of 1.43. CytomX Therapeutics Inc has a 1 year low of $12.51 and a 1 year high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.11). The business had revenue of $12.51 million for the quarter, compared to analysts’ expectations of $16.42 million. CytomX Therapeutics had a negative return on equity of 65.03% and a negative net margin of 68.90%. As a group, sell-side analysts anticipate that CytomX Therapeutics Inc will post -1.78 EPS for the current fiscal year.
Several analysts recently issued reports on the stock. BidaskClub lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. ValuEngine lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 17th. HC Wainwright set a $32.00 price objective on shares of CytomX Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 24th. Goldman Sachs Group initiated coverage on shares of CytomX Therapeutics in a report on Monday, October 15th. They issued a “neutral” rating and a $21.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $32.47.
In other CytomX Therapeutics news, CFO Debanjan Ray sold 3,000 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $18.46, for a total transaction of $55,380.00. Following the sale, the chief financial officer now directly owns 8,928 shares in the company, valued at $164,810.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sean A. Mccarthy sold 6,526 shares of the business’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $15.00, for a total transaction of $97,890.00. The disclosure for this sale can be found here. Insiders have sold 12,526 shares of company stock worth $198,270 over the last quarter. Insiders own 8.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “CytomX Therapeutics Inc (CTMX) Shares Bought by Sphera Funds Management LTD.” was reported by Equities Focus and is the sole property of of Equities Focus. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.equitiesfocus.com/2018/12/08/cytomx-therapeutics-inc-ctmx-shares-bought-by-sphera-funds-management-ltd.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Story: What type of investment options does a Roth IRA provide?
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.